• API

    20 plus years of expertise in developing APIs. Recognised for rich chemistry experience, quality, manufacturing capabilities, regulatory and IP capabilities

    Read more

  • Formulations

    One of the world leaders in developing & manufacturing branded/non-branded generics. More than 200 marketed products and 150 ANDAs filed across most therapeutic areas.

    Read more

  • ARV

    One of the world’s largest global producer of anti-retroviral drugs. Over 30 US FDA and WHO PQ approved ARV molecules and combinations in ARV portfolio.

    Read more

  • Biosimilars

    Our Biosimilar program focuses on development, manufacturing and commercialization of high value complex biosimilars including monoclonal antibodies.

    Read more

News & Events

  • 03 Aug 2015
  • Hetero announces the launch of Biosimilar Rituximab (MABALL) in India
  • India, Hyderabad, 3rd August 2015: Hetero group, one of India's leading generic pharmaceutical companies and one of the world's largest global producer of anti-retroviral drugs for HIV/AIDS treatment, today announces the successful launch of its biosimilar? Rituximab? under the brand name MABALL in India. Read more